Key Highlights
•
A new study shows that combining the arthritis drug ixekizumab with the weight-loss drug tirzepatide leads to better disease control in people with psoriatic arthritis who are also overweight or obese, compared to using ixekizumab alone. This is significant because it addresses the common overlap of arthritis and metabolic issues, offering a more effective treatment strategy that improves both joint symptoms and overall health.
Source →
•
Researchers have developed a new type of targeted therapy using cellular nanovesicles that carry the chemotherapy drug oxaliplatin directly to pancreatic cancer cells, showing superior treatment effects. This approach represents a promising advance in cancer therapy by improving drug delivery to the tumor while potentially reducing side effects on healthy tissues.
Source →
•
A real-world study found that using a lower dose of the cancer drug bevacizumab alongside atezolizumab for liver cancer maintains the same anti-tumor effectiveness while significantly reducing common side effects like proteinuria and rash. This finding is important as it suggests doctors can make this powerful treatment more tolerable for patients without compromising its ability to fight the cancer.
Source →
•
A large safety review by the FDA found that the Crohn’s disease treatment ustekinumab does not carry a large increased risk of serious infections compared to other similar medications. This provides reassurance for patients and doctors about the safety profile of this important treatment option for inflammatory bowel disease.
Source →
Upgrade with 50% Off — Coupon: ERWMCWYU
Stay curious. Stay informed — with
Science Briefing.
This is a one time Briefing, Upgrade to continue.
